iRegene's NouvSight001 Receives Clinical Trial Clearance in the U.S. and China for Retinitis Pigmentosa#China#Chengdu#retinitis_pigmentosa#iRegene_Therapeutics#NouvSight001
iRegene's NouvSight001 Receives Clinical Trial Clearance in the U.S. and China for Retinitis Pigmentosa
iRegene Therapeutics advances its cell therapy NouvSight001, cleared for clinical trials in the U.S. and China, targeting retinitis pigmentosa.
third-news.com
September 29, 2026 at 5:47 AM
iRegene's NouvSight001 Receives Clinical Trial Clearance in the U.S. and China for Retinitis Pigmentosa#China#Chengdu#retinitis_pigmentosa#iRegene_Therapeutics#NouvSight001